Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial

Yann GouëfficGiovanni TorselloThomas ZellerGiovanni EspositoFrank VermassenKlaus Armin HauseggerGunnar TepeMarcus ThiemeMichael GschwandtnerAndrea KahlbergMarc SchindewolfMarc SapovalJuan Diaz-CartelleKonstantinos StavroulakisGroupe Hospitalier Paris St. Joseph,Department of Vascular and Endovascular Surgery,Paris,France (Y.G.).St. Franziskus-Hospital Münster,Münster,Germany (G.T.).Universitäts-Herzzentrum Freiburg-Bad Krozingen,Bad Krozingen,Germany (T.Z.).Department of Advanced Biomedical Sciences,University of Naples Federico II,Italy (G.E.).Gent University Hospital,Belgium (F.V.).Klinikum Klagenfurt am Wörthersee,Austria (K.A.H.).Klinikum Rosenheim,Germany (G.T.).REGIOMED Vascular Center Sonneberg,Germany (M.T.).Jena University Hospital,Clinic for Internal Medicine I,Germany (M.T.).Medizinische Universität Wien,Vienna,Austria (M.G.).Vita-Salute University,San Raffaele Scientific Institute,Milan,Italy (A.K.).Division of Angiology,Swiss Cardiovascular Center,Inselspital,Bern (M. Schindewolf).University Hospital,University of Bern,Switzerland (M. Schindewolf).Hôpital Européen Georges-Pompidou,Paris,France (M. Sapoval).Boston Scientific Corp,Marlborough,MA (J.D.-C.).Ludwig-Maximilian University,Munich,Germany (K.S.).,Luca Apruzzi Domenico Baccellieri Florian Bea Jean-Pierre Becquemin Clare Bent Luca Bertoglio Aurélia Bianchini Thomas Bieri Erwin Blessing Phillipe Chaillou Roberto Chiesa Costantino Del Giudice Koen Deloose Pascal Desgranges Christian Erbel Christine Espinola-Klein Patrick Feugier Inge Fourneau Gerd Grözinger Loic Guillemot Mohammed Hamady Britta Heilmeier Jeroen Hendriks Ounali Jaffer Nirmal Kakani Koen Keirse Christof Kranewitter Miltaidis Krokidis Ralf Langhoff Michael Lee Paul Lohle Lieven Maene Andreas Mahnken Lars Maiwald Daniele Mascia Andrea Melloni Piero Montorsi Colin Nice Alexander Oberhuber Christian Paetzel Greg Ramjas Christos Rammos Enrico Rinaldi Eugenio Rosset Rafael Ruiz Salmeron Concetta Saracino Antoine Sauguet Jost Phillipp Schäfer Nadjib Schahab Nicola Settembre Elisa Simonini Jonathan Sobocinski Eric Steinmetz Fabien Thaveau Hans van Overhagen Jurgen Verbist Niels Zorger

DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.059606

IF: 37.8

2022-10-20

Circulation

Abstract:A clear patency benefit of a drug-eluting stent (DES) over a bare metal stent (BMS) for treating peripheral artery disease of the femoropopliteal segment has not been definitively demonstrated. The EMINENT study (Trial Comparing Eluvia Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery) was designed to evaluate the patency of the Eluvia DES (Boston Scientific, Marlborough, MA), a polymer-coated paclitaxel-eluting stent, compared with BMS for the treatment of femoropopliteal artery lesions. EMINENT is a prospective, randomized, controlled, multicenter European study with blinded participants and outcome assessment. Patients with symptomatic peripheral artery disease (Rutherford category 2, 3, or 4) of the native superficial femoral artery or proximal popliteal artery with stenosis ≥70%, vessel diameter of 4 to 6 mm, and total lesion length of 30 to 210 mm were randomly assigned 2:1 to treatment with DES or BMS. The primary effectiveness outcome was primary patency at 12 months, defined as independent core laboratory–assessed duplex ultrasound peak systolic velocity ratio ≤2.4 in the absence of clinically driven target lesion revascularization or surgical bypass of the target lesion. Primary sustained clinical improvement was a secondary outcome defined as a decrease in Rutherford classification of ≥1 categories compared with baseline without a repeat velocity ratio ≤2.4 in the absence of clinically driven target lesion revascularization. Health-related quality of life and walking function were assessed. A total of 775 patients were randomly assigned to treatment with DES (n=508) or commercially available BMS (n=267). Baseline clinical, demographic, and lesion characteristics were similar between the study groups. Mean lesion length was 75.6±50.3 and 72.2±47.0 mm in the DES and BMS groups, respectively. The 12-month incidence of primary patency for DES treatment (83.2% [337 of 405]) was significantly greater than for BMS (74.3% [165 of 222]; P <0.01). Incidence of primary sustained clinical improvement was greater among patients treated with the DES than among those who received a BMS (83.0% versus 76.6%; P =0.045). The health-related quality of life dimensions of mobility and pain/discomfort improved for the majority of patients in both groups (for 66.4% and 53.6% of DES-treated and for 64.2% and 58.1% of BMS-treated patients, respectively) but did not differ significantly. At 12 months, no statistical difference was observed in all-cause mortality between patients treated with the DES or BMS (2.7% [13 of 474] versus 1.1% [3 of 263]; relative risk, 2.4 [95% CI, 0.69–8.36]; P =0.15). By demonstrating superior 1-year primary patency, the results of the EMINENT randomized study support the benefit of using a polymer-based paclitaxel-eluting stent as a first-line stent-based intervention for patients with symptomatic peripheral artery disease attributable to femoropopliteal disease. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02921230.

cardiac & cardiovascular systems,peripheral vascular disease